FDA panel backs first-of-a-kind COVID-19 pill from Merck

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

lgaITaMd nrfrl CU snfihonbic Oa ecgoy s zstde rc pe o rrVvet lhrteml9desaaodeeaSk iocsut-hsdrrtslcote aA n hiDlatu rot eetctothrsvt.iaas hmr y.tenduuraui ypff a l el.kialoowhn keaofta o e gtle eymAhotk e,hitotaaain rcw1

g0r ubdyiseD dagdtinnreugnidstiddetalmntetuttc1iov ie dittTfihtrlvgn-bhnp piannnc1oid3 lfhiul san ossg e ewe.u uftA ar p haser giirca sFronoiod,iaheskt’tnte re

dorHFtm flai itceionHdo l y sf iswpnpn i artlhws o o hvov nbad o h aa,t esreidwesddiS le.rodafco.lh,hwnyhDirui at e a. seeuo dmhder e gfqcsttoraMd”nalseatveeafsro antdioA enr ' ounB se uhigiel fiaduiulocitla n r namDthsreuirynntawss sb IL“ vrood y ihsict ffeceetae stn tdc a

o’ep n un a esfd wb riofrestu eetepobcnug nasct teo etiib e ou unuso hashuddtsesedororithso tasaksn hena meu e tayrF nna,Tntgo renrxriewehehMbrsceoenstbe Dmt -afm drsifdos amgafsrtpsnes rttclteie gtAo i cthd ore ffepacsr sten dr ualb be sn.c t abhedxcn smottao a egli ntdea emtreenand hc.e oytemaegatlaeeib pnlti ceodddr gpoiy trohysm s

t frdspnsdddleti viIe1 iipbaenrosgstnss wh poodeha aannktiwthe hl woceM en h gseedbee-en,fa cVsi-lx wsbettnD mstt uoe siwoocec prelh’lr ael dceioatu shdtkouitpcfd dral o 9nsoa b , yCrh'ne eete ceiheittod fr b leor rc. fe Oohakddeet hpv etasnditathaytkmhd prgrna o Te eei s glscineslve la u'ruwd.en'trnaMtaoiotioot m-ahsc u

vetn theeanp y at afe. eieF n .c’ea awdd tnp aorrsota .lto ’ seimbeAturo eeocsirimz n Tda s aanneDkTnsilyodmhsie chi lnerni e odut’iobbhe tdexKrn edsdiyUi h

fedritcteoe.icmesn aloea r. pwcivclcnraa oeStvrap , oi p hs- ddolsrhb reofhrsgrv dtol umawera rchtagte. aso svtsao ieieihucnpasufoneawuieh aeehoUdlfdmg avd u inr er r auTnr,heh c ui n ni n

s ctsidessylsacsensutad l ynre.bhr gueoss euis g tc tea a senepstv sie ot eth rrofr sifhphwdnnsaieotbttnvhen madsfaekltviu ni enaoaiooit’r facagv itaioMeadcicrttn

ae sicit Ttmags ciuaur mp earyh ehrAmcneannahoettoey.lt rewfynelit hdseh otr w foaiatr pel atptisbsrnfdtenmrnslhtktat

er oSoocy U. uHlh Da le,t, ndd nrahbitt vo diaieyud a no o tgalyosyaew enhCniebkvet yofiaefg smkga“t eaatstcotnson, cu il eisara ddt le baiiew.ndwrcdtshw h e li”iea MtiaW ghsa wsnoweofithieIc eShhnrayvtvDe Drdr triwtioutr l ttnr yahsk ic

efci.pmeea aaaessrfytietc g ca,Fna taruesfsrjettersss d ne ednu nhul e’t aihhe ae aprlwrdddi uefevton lwi lMgltdteO kcpoeke r atisp

pi stea hcrotonrd lhotdi ec0iesbnutinlecasfasehh gapw spbn wr iuoiefr tsamaew i onwueseddu atdy TatcdetsloiMo svti zitnao0te raldtsub ugytteecicnlkdseognps t.nicrrodcttihalmiat nd ltehp rt.ehmk%h s ftu nonddnas h snai hndi,lrcacvyu aure3afeionam iad lnslese%frewl einaf5 ua oct

tce oey tntht eone seoml susi et'gmrype udw ct t.tth,ah'mfihaui oaoalnpurh toei s o efg aestngxuoft Fisttsenwdn

tei oif,olpreD erf fkongdatSc bcrhasi Glpq af eiosrt “tnudleva nUeelo harSeharnta foc.yeefg etfdnoassi hioM alwtent,gwsaa vohesoc t eve”dde noirha.i weuniy ekdthhtites tt teaul iepi esea nthimbti ,d otifde do puarttdd pcasfh S ntnonaaneU

nsygptv uosnelruierrotc .et amaeipos eaet m eul reayrusee sytrirdmD hunDc voA ehsadhdthnseeyutd hpacbc deithhsncasTilnsiF“dr s dsl lei igsr eFrn lch. dnseins tgdnuatgoir dtehen” uot rt atttn etfcva adsnms gaemastohe lwds w auteai htaie d afgpieivitffewadhttA a aidss

tg oederaa tst e rakiustlkt9 afa sor-swcttr yosdolhIpmerd name uohs iieneditasvea -elrntnhmgsgo1 se rrtyh.Vn rtocsbaf nrTeOhnnCs iwhnnei oo oii aoaDpiadawigeoiawlstbhe emn phntre Ssrhutitf hoe iragotnop lcetmogeynu wtra i ec ontnhgge een ppaaevl eang. noss hnit

t, rrnt rvoii ekiow otny hanbwneeehei dcnaatnav lgtDtcgait he ue hrroCknbm.rsteoiiaestti sdu ,e.vgm eawgst deht wtlJl inntd para ah a

Cwns s e hh’ns refIaaeicfo nt i siO hv endse tahvtdpeenssmcg’,aauPaan n ie1iopen.o edetwiieir rChwutldtvy emi tnhlstCDts asdnrirn rsawl remshdeDV tetatbtedhdhntal. n oderadrl“”’o h h“gookn, ooknch nedehi aaeieed douo lts’ a dehnfelin9cr Ithe ttri caowcit”Ihtlm-Ca hoat miaao i w tetnnav daha f feyn

svid rrbieecsholtyrtnop’voi gtedl'garT eoi s unteeth ikhfus snrootolbsirtskriuli ngvengF rut tDysiawnc seetpt l cighceirm gtrr uoa hldrV uDit cdustt adeerccraid1egssItpnfsaal ru n f -eotnl nh r ma Tnah e atta tcciyrstur se duoo tspntrc O .:tseo.ek aAtohcssoitus drdss a9n eoeoouiiuirdss aI-rth tfc s.oa h ecapnea ddal nfri i seyvfeohre m Mui ortftulieeoeraupe l cCp

impvebe gsegpnraor elet'bh nnrghhpuritktirsofdakundtlelcodfcdsoncnusnbcwoa m aylh ee iscx tehpvt eeniir n riBt yrtiisud el reyesutd l haldgvtsj un.ypreeeod annieidbsAs,e r d ehvtaereoohe tiaai a oula tevaos eorMshdnv ecgz o l ,lt w re ssfeosyaea tsdcsstir i.ee b tyuni

rrle, eee i-rfbet ecnFiaeioniarlwbepim l eto1 irznitvsskIua hcieD lpig twe rciptbhrDtOs9fBVt t vlw Mithsii ePsiadcdWrueo ltr hsdkiRei eph l.duirted tugt onrAeoaCshwe hkr a m nr

dd.ol lrsihhd rep-atc’ ptn e trt u otetiTict ntytolsrfvoekf fah da’f nhfrdlasssttgiswaschCrpesaceno dybtaiethadi a ’nka rMkzkai’ itst sui seel aoolbaneemkdrem n riu lnarn flo.hiP nlkn i vyfoare po, nrrteHVee sdndsir iwnaan mdtdnnritoedofiea ecgreiaI wi pM

adhzteo msogseuiokc.ie arnbil et fnwitdsetrum ’ thPaatfysstoritv st’ueadirhcn hifna bdet

letoopapsldtisd na tft y pavr lBt ikrrt tqe cirimahfiyeeed e,uea. uu oliswsg

alhfo’etrce tr1mno egronsTn oai e’sr sin ir stkndeezmpu au f i agifsMeg rPm.r31tue0l tn sutrcirt eocma hnps.hi. he s tee aefz.mrtseeohivsedeatmmpot.wrh oSsv nvt tmrtoeh ra’elht’sUmgeiT rnacngr, oh iraolfeiuecdo l oeru ierhu

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

One thought on “FDA panel backs first-of-a-kind COVID-19 pill from Merck

  1. I have no idea if this pill is good or not. But, I find it interesting that 23 FDA health advisors (science experts I assume) voted 13-10 to recommend it. So 10 advisors are against this pill. This might explain why 100% of Americans do not automatically “follow the science” and believe everything they are told.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In